Molecular profiling reveals clinically actionable mutations and translocations in myeloid sarcoma, highlighting the prognostic utility of targeted next-generation sequencing.
Myeloid sarcoma (MS) is a subgroup of acute myeloid leukemia (AML) where myeloid blasts form a tumoral mass in extramedullary tissues [1]. MS may occur at any point during the disease course and al...
No takes yet. Share an insight, caveat, or question.
Kashofer et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: